Skip to main
IVA
IVA logo

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA is a biopharmaceutical company focusing on innovative treatments for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies, and its lead product candidate, lanifibranor, has shown promising results in improving fibrosis and metabolic markers. The positive outlook is bolstered by lanifibranor's unique ability to achieve both MASH resolution and significant fibrosis improvement in clinical trials, with a notable 42% improvement compared to placebo, which could establish it as a best-in-class option in its therapeutic category. Additionally, the potential for lanifibranor to complement existing therapies, particularly GLP-1s, may enhance market adoption and support revenue growth through strategic partnerships, reinforcing Inventiva's financial position in the competitive biopharmaceutical landscape.

Bears say

Inventiva SA faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from its financial losses and clinical development risks. The company reported a net loss of €175.9 million, or €1.62 per share, indicating ongoing financial strain that may limit future operational capabilities. Additionally, potential efficacy or safety issues with its lead product candidate, lanifibranor, in Phase III development, as well as the risk of clinical trial failures and delays in regulatory timelines, further exacerbate concerns regarding the company’s future growth and valuation.

Inventiva S.A. (IVA) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Inventiva S.A. (IVA) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.